Autopsy report · NCT01649258

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

“Lack of Efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 5 years 1 month before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University of Southern California

Sponsor type

University, hospital or other

Conditions

Breast Cancer; Nausea; Vomiting

Interventions

granisetron transdermal system; fosaprepitant dimeglumine; laboratory biomarker analysis

Participants

29

Sites

1

Countries

United States

Trials that died the same way

• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (91% match in meaning)
• Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
  “lack of efficacy and lack of funding” (85% match in meaning)
• Influence of Esmolol on a Closed-Loop Anesthesia System
  “lack of effectiveness” (81% match in meaning)
• Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
  “Lack of efficacy of treatment tested” (77% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.